<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795209</url>
  </required_header>
  <id_info>
    <org_study_id>B-1207-162-005</org_study_id>
    <secondary_id>B-1207-162-005</secondary_id>
    <nct_id>NCT01795209</nct_id>
  </id_info>
  <brief_title>Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision</brief_title>
  <acronym>RVOFV</acronym>
  <official_title>Phase 4 Study of Ranibizumab for the Treatment of Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Initial Fair Visual Acuity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of ranibizumab for the treatment of&#xD;
      macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in patients with initial&#xD;
      fair visual acuity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lucentis was approved for ME due to BRVO based on the results from BRAVO study. The inclusion&#xD;
      criteria in BRAVO was &quot;best corrected visual acuity (BCVA) 20/40 to 20/320&quot;. Therefore, the&#xD;
      patients with VA better than 20/40 who are out of inclusion criteria of BRAVO study had no&#xD;
      treatment and just wait to reach spontaneous improvement. But, there is unmet needs of these&#xD;
      patients and, in actual clinical practice, many retina specialists treat these patients with&#xD;
      Ranibizumab. These patients have been experiencing VA improvement after the injection. Based&#xD;
      on these clinical backgrounds, the investigator wants to suggest the treatment guidelines in&#xD;
      these patients group, which is, early treatment of ranibizumab would be effective and&#xD;
      increase patients' QOL. In other words, there are many experiences in these cases among&#xD;
      ophthalmologists, but there have been no clinical trials that can endorse the treatments. To&#xD;
      confirm the efficacy of ranibizumab in patients with initial fair vision, the investigators&#xD;
      started the prospective randomized clinical trial on the efficacy and safety of ranibizumab&#xD;
      for the patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient enrollment&#xD;
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to achieve an improvement of 10 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters in best-corrected visual acuity</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline ETDRS letter score over time</measure>
    <time_frame>6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients gaining 10 or more letters in ETDRS letter score from baseline BCVA</measure>
    <time_frame>6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients gaining &lt; 10 letters in ETDRS letter score from baseline BCVA</measure>
    <time_frame>6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients losing &lt; 10 letters in ETDRS letter score from baseline BCVA</measure>
    <time_frame>6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with who at least maintain baseline BCVA</measure>
    <time_frame>6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with central foveal thickness (CFT) of &lt; 300 um</measure>
    <time_frame>6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety outcomes</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>Frequency, type, and severity of adverse reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline CFT over time</measure>
    <time_frame>6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) distance activities subscale score</measure>
    <time_frame>6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in contrast sensitivity</measure>
    <time_frame>6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in multifocal electroretinogram (mfERG) P1 amplitude</measure>
    <time_frame>6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients losing 10 or more letters in ETDRS letter score from baseline BCVA</measure>
    <time_frame>6 months and 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Branch Retinal Vein Occlusion</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ranibizumab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive three monthly injections of 0.5 mg of Lucentis (0.05 ml), followed by retreatment/rescue laser as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive three monthly sham injections, followed by retreatment/rescue laser as needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Loading dose: three monthly intravitreal injections of ranibizumab 0.5 mg&#xD;
Lucentis stop criteria: V/A ≥20/20 and complete disappearance of macular edema&#xD;
Retreatment: visual loss of 5 or more letter compared to previous visit</description>
    <arm_group_label>Ranibizumab group</arm_group_label>
    <other_name>Lucentis(ranibizumab), 3mg/0.3ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <description>Three monthly sham injections followed by retreatment (sham injections) as needed&#xD;
Stop criteria: V/A ≥20/20 and complete disappearance of macular edema&#xD;
Retreatment: visual loss of 5 or more letter compared to previous visit</description>
    <arm_group_label>Standard of care group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rescue laser</intervention_name>
    <description>In the Lucentis group: performed if BCVA &lt; 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6&#xD;
In the standard of care group: performed if BCVA &lt; 20/40 or CFT ≥ 350um from Month 3</description>
    <arm_group_label>Ranibizumab group</arm_group_label>
    <arm_group_label>Standard of care group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Foveal center-involving macular edema secondary to BRVO diagnosed within 12 months&#xD;
             before study enrollment&#xD;
&#xD;
          2. ETDRS chart BCVA: 63 to 77 letters (20/32 to 20/50 Snellen equivalent)&#xD;
&#xD;
          3. CFT &gt;= 300 um (mean of measurements obtained at screening and Day 0)&#xD;
&#xD;
          4. Signed consent informed&#xD;
&#xD;
          5. male or female, age ≥18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior episode of RVO: Past history of RVO in the study eye diagnosed before 1 year of&#xD;
             study enrollment.&#xD;
&#xD;
          2. BCVA improvement &gt;10 letters between screening and Day 0&#xD;
&#xD;
          3. History of other ocular diseases (e.g. diabetic retinopathy, age-related macular&#xD;
             degeneration)&#xD;
&#xD;
          4. Laser treatment within 3 months before baseline&#xD;
&#xD;
          5. Intraocular corticosteroid use within 3 months before baseline&#xD;
&#xD;
          6. Anti-vascular endothelial growth factor (VEGF) treatment in the study or fellow eye&#xD;
             within 3 months before baseline&#xD;
&#xD;
          7. Intraocular surgery other than cataract surgery, Cataract surgery within 6 months&#xD;
             before baseline&#xD;
&#xD;
          8. Stroke or myocardial infarction ≤3 months before baseline&#xD;
&#xD;
          9. Pregnancy or plan to have baby in female&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu Hyung Park, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National Univeristy Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Se Woong Kang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyunggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010 Jun;117(6):1102-1112.e1. doi: 10.1016/j.ophtha.2010.02.021. Epub 2010 Apr 15.</citation>
    <PMID>20398941</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Kyu Hyung Park</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Branch retinal vein occlusion</keyword>
  <keyword>Macular edema</keyword>
  <keyword>Ranibizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

